Hepatitis Be Panel Test in UAE | 200 AED | DNA Labs UAE

Executive Summary & Core Metrics

Diagnostic Accuracy: 99.9% clinical sensitivity via CLIA (Chemiluminescent Immunoassay) – exceeding traditional ELISA thresholds. Price: 200 AED all-inclusive. Turnaround: Results within 24 hours of sample receipt. Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM). Post-Test Support: Teleconsultation with a licensed physician to interpret your HBeAg and Anti-HBe results.

Test Overview & Methodology

The Hepatitis Be Panel quantifies Hepatitis B e Antigen (HBeAg) and its corresponding antibody (Anti-HBe) to determine viral replication activity, seroconversion phase, and infectivity risk in individuals with chronic hepatitis B virus (HBV) infection. A positive HBeAg indicates active viral replication and higher transmissibility; seroconversion to Anti-HBe suggests reduced replication and a transition to the inactive carrier state. This distinction directly guides antiviral therapy decisions and long-term hepatocellular carcinoma surveillance.

Parameter	DNA Labs UAE	Standard Laboratory
Methodology	CLIA – enhanced chemiluminescent sensitivity	ELISA – lower analytical sensitivity
Turnaround Time	Same-day / within 24 hours	2–3 business days
Price (AED)	200	250+
Home Collection	Included – ISO-certified cold chain & VIP phlebotomy	Not available or surcharge applies

Physician Insight & Safety Protocols

“Monitoring HBeAg and Anti-HBe is essential for staging chronic hepatitis B and personalizing antiviral regimens. Seroconversion from e-antigen positive to e-antibody positive marks a critical turning point in disease management, reducing the risk of cirrhosis and liver cancer. I recommend this panel for all patients with chronic HBV to guide treatment decisions and confirm immune control.”

— Dr. Ajay Singh | General Practitioner | DHA Registration ID: 36234132

Advisory on Antiviral Continuity

⚠️ Do Not Discontinue Prescribed Therapy

Abrupt cessation of nucleos(t)ide analogues or interferon can trigger a severe hepatitis flare, hepatic decompensation, and rebound viremia. Always consult your hepatologist before altering any medication regimen.

Safety Exclusion & Emergency Red Flags

Exclusion Criteria & Urgent Warning Signs

Exclusion: Patients with acute liver failure, decompensated cirrhosis (Child-Pugh C), or inability to provide a venous blood sample.
Emergency Red Flags: New-onset jaundice, severe right upper quadrant pain, confusion or altered mental status, easy bruising or bleeding — seek immediate emergency care.

Patient FAQ & Clinical Guidance

1. What does the Hepatitis Be Panel detect?

The panel measures two biomarkers: Hepatitis B e Antigen (HBeAg) and Hepatitis B e Antibody (Anti-HBe). HBeAg positivity indicates active viral replication and high infectivity; Anti-HBe positivity suggests seroconversion, lower replication, and often a favorable treatment response. Your physician uses these results together with HBV DNA and liver enzymes to stage disease and tailor therapy.

2. Why is this test needed if I already have chronic hepatitis B?

Regular HBeAg/Anti-HBe monitoring tracks seroconversion status — a key milestone that signals a transition from the immune-active phase to the inactive carrier state. This information helps your doctor decide when to start, adjust, or stop antiviral medications, ultimately reducing the risk of cirrhosis and hepatocellular carcinoma.

3. How is the home sample collection performed?

A certified phlebotomist arrives at your residence within a scheduled window (daily 8 AM – 11 PM) carrying an ISO-rated temperature-controlled transport kit. A standard venous blood draw is collected, labeled, and immediately stabilized under cold-chain conditions. The specimen reaches our ISO-accredited laboratory within hours, and results are uploaded to your secure patient portal within 24 hours.

UAE Regulatory & Data Privacy Adherence

This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient health information is encrypted at rest and in transit, accessed only by authorized clinical personnel, and processed under ISO 9001:2015 certified workflows. Clinical safety and patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability.

Clinical & Logistical Metadata

Test Name	Hepatitis Be Panel (HBeAg & Anti-HBe)
Price (AED)	200
Turnaround Time	24 hours from sample receipt
Sample Type / Matrix	Serum or Plasma (venous blood)
Methodology Used	CLIA (Chemiluminescent Immunoassay)
ICD-10-CM Code	B18.1, B16.9, Z11.59
LOINC Code	51825-9
DHA Facility License & Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE